114 related articles for article (PubMed ID: 18645261)
1. A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer.
Schrohl AS; Mueller V; Christensen IJ; Pantel K; Thomssen C; Bruenner N
Tumour Biol; 2008; 29(3):181-7. PubMed ID: 18645261
[TBL] [Abstract][Full Text] [Related]
2. Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer.
Sørensen NM; Schrohl AS; Jensen V; Christensen IJ; Nielsen HJ; Brünner N
Scand J Gastroenterol; 2008; 43(2):186-91. PubMed ID: 18224564
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.
Wu ZS; Wu Q; Yang JH; Wang HQ; Ding XD; Yang F; Xu XC
Int J Cancer; 2008 May; 122(9):2050-6. PubMed ID: 18172859
[TBL] [Abstract][Full Text] [Related]
4. Plasma Levels and Diagnostic Utility of Macrophage Colony-Stimulating Factor, Matrix Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinases-1 as New Biomarkers of Breast Cancer.
Ławicki S; Głażewska EK; Sobolewska M; Będkowska GE; Szmitkowski M
Ann Lab Med; 2016 May; 36(3):223-9. PubMed ID: 26915610
[TBL] [Abstract][Full Text] [Related]
5. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer.
Lipton A; Ali SM; Leitzel K; Demers L; Evans DB; Hamer P; Brown-Shimer S; Pierce K; Carney W
Cancer; 2007 May; 109(10):1933-9. PubMed ID: 17407159
[TBL] [Abstract][Full Text] [Related]
6. Tissue inhibitor of metalloproteinase-1 levels in plasma from tumour arteries and veins of patients with rectal cancer.
Frederiksen C; Lykke J; Christensen IJ; Brünner N; Nielsen HJ
Scand J Clin Lab Invest; 2007; 67(5):545-52. PubMed ID: 17763191
[TBL] [Abstract][Full Text] [Related]
7. Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer.
Holten-Andersen MN; Christensen IJ; Nielsen HJ; Stephens RW; Jensen V; Nielsen OH; Sørensen S; Overgaard J; Lilja H; Harris A; Murphy G; Brünner N
Clin Cancer Res; 2002 Jan; 8(1):156-64. PubMed ID: 11801553
[TBL] [Abstract][Full Text] [Related]
8. Plasma levels of the MMP-9:TIMP-1 complex as prognostic biomarker in breast cancer: a retrospective study.
Thorsen SB; Christensen SL; Würtz SO; Lundberg M; Nielsen BS; Vinther L; Knowles M; Gee N; Fredriksson S; Møller S; Brünner N; Schrohl AS; Stenvang J
BMC Cancer; 2013 Dec; 13():598. PubMed ID: 24330623
[TBL] [Abstract][Full Text] [Related]
9. Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer.
Klintman M; Ørnbjerg Würtz S; Christensen IJ; Braemer Hertel P; Fernö M; Malmberg M; Mouridsen H; Cold F; Schrohl AS; Foekens JA; Malmström P; Brünner N
Breast Cancer Res Treat; 2010 Jun; 121(2):365-71. PubMed ID: 19653096
[TBL] [Abstract][Full Text] [Related]
10. Tumor tissue inhibitor of metalloproteinases-1 (TIMP-1) in hormone-independent breast cancer might originate in stromal cells, and improves stratification of prognosis together with nodal status.
Kuvaja P; Hulkkonen S; Pasanen I; Soini Y; Lehtonen S; Talvensaari-Mattila A; Pääkkö P; Kaakinen M; Autio-Harmainen H; Hurskainen T; Lehenkari P; Turpeenniemi-Hujanen T
Exp Cell Res; 2012 Jun; 318(10):1094-103. PubMed ID: 22465225
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of proteolytic activity imbalance in breast cancer diagnosis.
Swellam M; Soliman HA; Abdelmaksoud MD; Nageeb AM; El Arab LR; Boshnak H
Cancer Biomark; 2014; 14(6):409-17. PubMed ID: 25335732
[TBL] [Abstract][Full Text] [Related]
12. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
13. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer.
Holten-Andersen MN; Murphy G; Nielsen HJ; Pedersen AN; Christensen IJ; Høyer-Hansen G; Brünner N; Stephens RW
Br J Cancer; 1999 May; 80(3-4):495-503. PubMed ID: 10408859
[TBL] [Abstract][Full Text] [Related]
14. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer.
Holten-Andersen MN; Stephens RW; Nielsen HJ; Murphy G; Christensen IJ; Stetler-Stevenson W; Brünner N
Clin Cancer Res; 2000 Nov; 6(11):4292-9. PubMed ID: 11106246
[TBL] [Abstract][Full Text] [Related]
15. Expression and prognostic significance of fibronectin and matrix metalloproteases in breast cancer metastasis.
Fernandez-Garcia B; Eiró N; Marín L; González-Reyes S; González LO; Lamelas ML; Vizoso FJ
Histopathology; 2014 Mar; 64(4):512-22. PubMed ID: 24117661
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer.
Komorowski J; Pasieka Z; Jankiewicz-Wika J; Stepień H
Thyroid; 2002 Aug; 12(8):655-62. PubMed ID: 12225633
[TBL] [Abstract][Full Text] [Related]
17. Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer.
Lipton A; Leitzel K; Chaudri-Ross HA; Evans DB; Ali SM; Demers L; Hamer P; Brown-Shimer S; Pierce K; Gaur V; Carney W
J Clin Oncol; 2008 Jun; 26(16):2653-8. PubMed ID: 18443351
[TBL] [Abstract][Full Text] [Related]
18. Plasma and serum levels of tissue inhibitor of metalloproteinases-1 are associated with prognosis in node-negative breast cancer: a prospective study.
Würtz SØ; Møller S; Mouridsen H; Hertel PB; Friis E; Brünner N
Mol Cell Proteomics; 2008 Feb; 7(2):424-30. PubMed ID: 17998244
[TBL] [Abstract][Full Text] [Related]
19. High serum TIMP-1 correlates with poor prognosis in breast carcinoma - a validation study.
Kuvaja P; Würtz SØ; Talvensaari-Mattila A; Brünner N; Pääkkö P; Turpeenniemi-Hujanen T
Cancer Biomark; 2007; 3(6):293-300. PubMed ID: 18048967
[TBL] [Abstract][Full Text] [Related]
20. Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study.
Willemoe GL; Hertel PB; Bartels A; Jensen MB; Balslev E; Rasmussen BB; Mouridsen H; Ejlertsen B; Brünner N
Eur J Cancer; 2009 Sep; 45(14):2528-36. PubMed ID: 19535243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
